The company has repaid debt of about $580 million in Fy21. The sale of branded formulations in India business for Q4 FY21 stood at Rs 2,670.90 crore, rising 12.9% over Q4 FY20, accounting for 31.7% of total sales. Sun Pharmaceutical Industries holds approximately 8.2% market share in the over Rs 1,474 billion Indian pharmaceutical market as per AIOCD AWACS MAT March 2021 report. For Q4 FY21, the company launched 31 new products in the Indian market. For US formulations (including Taro), sales were at $370 million, recording a decline of 1.3% over Q4 last year and accounting for about 32% of total consolidated sales. Taro, a US-based...